Predict your next investment

JMI Laboratories company logo
HEALTHCARE | Medical Facilities & Services / Medical Laboratories & Research
jmilabs.com

See what CB Insights has to offer

About JMI Laboratories

JMI Laboratories is a microbiology laboratory supporting companies in their development of antimicrobials.

JMI Laboratories Headquarter Location

345 Beaver Kreek Center Suite A

North Liberty, Iowa, 52317,

United States

319-665-3370

Latest JMI Laboratories News

Spero Therapeutics to Present Data at IDWeek 2021

Sep 16, 2021

September 16, 2021 08:05 ET Cambridge, Massachusetts, UNITED STATES CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced 23 data presentations at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 – October 3, 2021. Presentations will showcase in vitro and in vivo studies of Spero’s oral antibiotic investigational candidate tebipenem HBr for the treatment of adults with complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) and highlight additional research on the epidemiology and management of cUTI. Presentations pertaining to tebipenem HBr and the epidemiology and management of cUTI: 1. Title: Tebipenem in vitro activity against a collection of pathogens responsible for urinary tract infections in the US  Presenting Author: Rodrigo Mendes, PhD (Director, JMI Laboratories) Date: Wednesday, September 29, 2021 Poster Session: A1. Title: In vitro activity of tebipenem against clinically significant gram-negative bacteria isolated from patients with cancer Presenting Author: Bahgat Gerges, PhD (Research Scientist, MD Anderson Cancer Center) Date: Wednesday, September 29, 2021 Poster Session: A1. Novel Agents Poster Number: 1069 3. Title: Development of tebipenem MIC antimicrobial susceptibility test for gram-negative bacteria on MicroScan dried gram-negative MIC panels Presenting Author: Jose Enrique Fernandez (Development Scientist, Beckman Coulter) Date: Wednesday, September 29, 2021 Poster Session: A1. Novel Agents Poster Number: 1079 Presenting Author: Brian VanScoy, B.S. (Director, Institute for Clinical Pharmacodynamics) Date: Wednesday, September 29, 2021 Poster Session: A2. PK/PD Studies Poster Number: 1095 Presenting Author: Harish Ganesan, M.S. (Institute for Clinical Pharmacodynamics) Date: Wednesday, September 29, 2021 Poster Session: A2. PK/PD Studies Poster Number: 1105 6. Title: Oral tebipenem as step-down therapy following intravenous ertapenem in a 7-day hollow-fiber in vitro model Author: Brian VanScoy, B.S. (Director, Institute for Clinical Pharmacodynamics) Date: Wednesday, September 29, 2021 Poster Session: A2. PK/PD Studies Poster Number: 1113 7. Title: Absorption, metabolism, and excretion of [14C]-tebipenem pivoxil hydrobromide (TBP-PI-HBr) following a single oral dose in healthy male subjects Presenting Author: Vipul Gupta, PhD (Sr. Director, DMPK, Bioanalysis and Clinical Pharmacology, Spero Therapeutics) Date: Wednesday, September 29, 2021 Poster Session: A2. PK/PD Studies Poster Number: 1120 Presenting Author: Vipul Gupta, PhD (Sr. Director, DMPK, Bioanalysis and Clinical Pharmacology, Spero Therapeutics) Date: Wednesday, September 29, 2021 Poster Session: A2. PK/PD Studies Poster Number: 1121 9. Title: Effect of aluminum hydroxide/magnesium hydroxide/simethicone and omeprazole on the pharmacokinetics of tebipenem pivoxil hydrobromide (TBP-PI-HBr) in healthy adult subjects Presenting Author: Vipul Gupta, PhD (Sr. Director, DMPK, Bioanalysis and Clinical Pharmacology, Spero Therapeutics) Date: Wednesday, September 29, 2021 Poster Session: A2. PK/PD Studies Poster Number: 1122 10. Title: In vitro activity of tebipenem and comparators against Enterobacterales collected from patients with bloodstream infections as part of the 2019 global STEWARD surveillance program  Presenting Author: Ian Critchley, PhD (Vice President and Head of Clinical Microbiology, Spero Therapeutics) Date: Wednesday, September 29, 2021 Poster Session: A3. Resistance mechanisms Poster Number: 1226 11. Title: Molecular epidemiology of Escherichia coli causing urinary tract infections in the United States and in vitro activity of tebipenem, including against strain lineage and resistant subsets (2018-2020) Presenting Author: Rodrigo Mendes, PhD (Director, JMI Laboratories) Date: Wednesday, September 29, 2021 Poster Session: A3. Resistance mechanisms Poster Number: 1254 12. Title: An evaluation of tebipenem in vitro activity against a panel of Pseudomonas aeruginosa isolates with Efflux, AmpC, and OprD Mutations Presenting Author: Brian VanScoy, B.S. (Director, Institute for Clinical Pharmacodynamics) Date: Wednesday, September 29, 2021 Poster Session: A3. Resistance mechanisms Poster Number: 1281 Presenting Author: Rodrigo Mendes, PhD (Director, JMI Laboratories) Date: Wednesday, September 29, 2021 Poster Session: A6. New drug development (formerly L3) Poster Number: 1036 14. Title: In vitro activity of tebipenem, an orally available carbapenem agent, against a collection of surveillance Gram-positive clinical isolates Presenting Author: SJ Ryan Arends, PhD (Scientist, JMI Laboratories) Date: Wednesday, September 29, 2021 Poster Session: A6. New drug development (formerly L3) Poster Number: 1038 15. Title: In vitro activity of tebipenem against a recent collection of fastidious organisms recovered from respiratory tract infections  Presenting Author: SJ Ryan Arends, PhD (Scientist, JMI Laboratories) Date: Wednesday, September 29, 2021 Poster Session: A6. New drug development (formerly L3) Poster Number: 1041 16. Title: In vitro activity of tebipenem against relevant clinical isolates in the presence of pulmonary surfactant  Presenting Author: SJ Ryan Arends, PhD (Scientist, JMI Laboratories) Date: Wednesday, September 29, 2021 Poster Session: A6. New drug development (formerly L3) Poster Number: 1044 Presenting Author: Eric Hammelman, MBA (Principal, Health Management Associates) Date: Wednesday, September 29, 2021 Poster Session: C11. UTIs Poster Number: 1416 18. Title: High prevalence of fluoroquinolone-resistant urinary tract infection among US emergency department patients diagnosed with UTI, 2018-2020 Presenting Author: Brett Faine, PharmD, MS (University of Iowa) Date: Wednesday, September 29, 2021 Poster Session: C11. UTIs Presenting Author: Marya Zilberberg, MD, MPH (President & CEO, EviMed Research Group) Date: Wednesday, September 29, 2021 Poster Session: C11. UTIs Poster Number: 1430 23. Title: Epidemiology and 12-month antibiotic use in the outpatient setting among adult patients with complicated urinary tract infections: a retrospective database analysis Presenting Author: Thomas Lodise, PharmD, PhD (Professor, Pharmacy Practice, Albany College of Pharmacy and Health Sciences) Date: Wednesday, September 29, 2021 Poster Session: C11. UTIs About Spero Therapeutics Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases. Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP. Spero is also developing SPR720 as a novel oral therapy product candidate for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting. For more information, visit  https://sperotherapeutics.com . Investor Relations Contact:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing JMI Laboratories

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

JMI Laboratories is included in 1 Expert Collection, including Infectious Disease.

I

Infectious Disease

2,222 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

JMI Laboratories Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

JMI Laboratories Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.